International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.

Defesche, J. C. et al. Familial hypercholesterolaemia. Nat. Rev. Dis. Prim. 3, 17093 (2017).

pubmed: 29219151 doi: 10.1038/nrdp.2017.93

Watts, G. F. et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat. Rev. Cardiol. 17, 360–377 (2020).

pubmed: 31974482 doi: 10.1038/s41569-019-0325-8

Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459–2472 (2017).

pubmed: 28444290 pmcid: 5837225 doi: 10.1093/eurheartj/ehx144

Beheshti, S. O., Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J. Am. Coll. Cardiol. 75, 2553–2566 (2020).

pubmed: 32439005 doi: 10.1016/j.jacc.2020.03.057

Beheshti, S., Madsen, C. M., Varbo, A., Benn, M. & Nordestgaard, B. G. Relationship of familial hypercholesterolemia and high LDL cholesterol to ischemic stroke: the Copenhagen General Population Study. Circulation 138, 578–589 (2018).

pubmed: 29593013 doi: 10.1161/CIRCULATIONAHA.118.033470

Svendsen, K. et al. Risk of stroke in genetically verified familial hypercholesterolemia: a prospective matched cohort study. Atherosclerosis 358, 34–40 (2022).

pubmed: 36084445 doi: 10.1016/j.atherosclerosis.2022.08.015

Centers for Disease Control and Prevention. Tier 1 Genomic Applications Toolkit for Public Health Departments. CDC https://www.cdc.gov/genomics/implementation/toolkit/index.htm (2014).

Hu, P. et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 141, 1742–1759 (2020).

pubmed: 32468833 doi: 10.1161/CIRCULATIONAHA.119.044795

Ray, K. et al. World Heart Federation Cholesterol Roadmap 2022. Glob. Heart 17, 75 (2022).

pubmed: 36382159 pmcid: 9562775 doi: 10.5334/gh.1154

Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73, e285–e350 (2019).

pubmed: 30423393 doi: 10.1016/j.jacc.2018.11.003

Mach, F. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 41, 111–188 (2020).

pubmed: 31504418 doi: 10.1093/eurheartj/ehz455

National Institute for Health and Clinical Excellence. NICE Clinical Guideline 71: Familial hypercholesterolaemia: identification and management. NICE https://www.nice.org.uk/guidance/cg71/chapter/recommendations (2019).

Wiegman, A. et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J. 36, 2425–2437 (2015).

pubmed: 26009596 pmcid: 4576143 doi: 10.1093/eurheartj/ehv157

Ramaswami, U. et al. Current management of children and young people with heterozygous familial hypercholesterolaemia — HEART UK statement of care. Atherosclerosis 290, 1–8 (2019).

pubmed: 31536851 doi: 10.1016/j.atherosclerosis.2019.09.005

de Ferranti, S. D. et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. Circulation 139, e603–e634 (2019).

pubmed: 30798614 doi: 10.1161/CIR.0000000000000618

Gidding, S. S. et al. The agenda for familial hypercholesterolemia — a scientific statement from the American Heart Association. Circulation 132, 2167–2192 (2015).

pubmed: 26510694 doi: 10.1161/CIR.0000000000000297

Watts, G. F. et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart Lung Circ. 30, 324–349 (2021).

pubmed: 33309206 doi: 10.1016/j.hlc.2020.09.943

Cuchel, M. et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehad197 (2023).

doi: 10.1093/eurheartj/ehad197 pubmed: 37130090 pmcid: 10314327

Santos, R. D. et al. Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. J. Clin. Lipidol. 11, 160–166 (2017).

pubmed: 28391882 doi: 10.1016/j.jacl.2016.11.004

Pang, J. et al. Comparative aspects of the care of familial hypercholesterolemia in the ‘Ten Countries Study’. J. Clin. Lipidol. 13, 287–300 (2019).

pubmed: 30797720 doi: 10.1016/j.jacl.2019.01.009

Vallejo-Vaz, A. J. et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 398, 1713–1725 (2021).

doi: 10.1016/S0140-6736(21)01122-3

Tromp, T. R. et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 399, 719–728 (2022).

pubmed: 35101175 pmcid: 10544712 doi: 10.1016/S0140-6736(21)02001-8

Representatives of the Global Familial Hypercholesterolemia Community. Reducing the clinical and public health burden of familial hypercholesterolemia — a global call to action. JAMA Cardiol. 5, 217–229 (2020).

doi: 10.1001/jamacardio.2019.5173

Groselj, U., Wiegman, A. & Gidding, S. S. Screening in children for familial hypercholesterolaemia: start now. Eur. Heart J. 43, 3209–3212 (2022).

pubmed: 35511818 doi: 10.1093/eurheartj/ehac224

Vallejo-Vaz, A. J. et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 243, 257–259 (2015).

pubmed: 26408930 doi: 10.1016/j.atherosclerosis.2015.09.021

Wei, N. et al. A bibliometric analysis of familial hypercholesterolemia from 2011 to 2021. Curr. Probl. Cardiol. https://doi.org/10.1016/j.cpcardiol.2022.101151 (2022).

doi: 10.1016/j.cpcardiol.2022.101151 pubmed: 35545178

Nieuwlaat, R., Schwalm, J.-D., Khatib, R. & Yusuf, S. Why are we failing to implement effective therapies in cardiovascular disease? Eur. Heart J. 34, 1262–1269 (2013).

pubmed: 23376448 doi: 10.1093/eurheartj/ehs481

Uchmanowicz, I. et al. Optimising implementation of European guidelines on cardiovascular disease prevention in clinical practice: what is needed? Eur. J. Prev. Cardiol. 28, 426–431 (2021).

pubmed: 33611449 doi: 10.1177/2047487320926776

Jones, L. K., Brownson, R. C. & Williams, M. S. Applying implementation science to improve care for familial hypercholesterolemia. Curr. Opin. Endocrinol. Diabetes Obes. 29, 141–151 (2022).

pubmed: 34839326 doi: 10.1097/MED.0000000000000692

Bauer, M. S. & Kirchner, J. Implementation science: what is it and why should I care? Psychiatry Res. 283, 112376 (2020).

pubmed: 31036287 doi: 10.1016/j.psychres.2019.04.025

O’Shea, R., Ma, A. S., Jamieson, R. V. & Rankin, N. M. Precision medicine in Australia: now is the time to get it right. Med. J. Aust. 217, 559–563 (2022).

pubmed: 36436133 pmcid: 10100177 doi: 10.5694/mja2.51777

Sarkies, M. N., Jones, L. K., Gidding, S. S. & Watts, G. F. Improving clinical practice guidelines with implementation science. Nat. Rev. Cardiol. 19, 3–4 (2022).

pubmed: 34799708 doi: 10.1038/s41569-021-00645-x

Migliara, G. et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Front. Public Health 5, 252 (2017).

pubmed: 28993804 pmcid: 5622145 doi: 10.3389/fpubh.2017.00252

Brouwers, M. C. et al. Development and validation of a tool to assess the quality of clinical practice guideline recommendations. JAMA Netw. Open 3, e205535 (2020).

pubmed: 32459354 pmcid: 7254179 doi: 10.1001/jamanetworkopen.2020.5535

Jacobson, T. A. et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1 — full report. J. Clin. Lipidol. 9, 129–169 (2015).

pubmed: 25911072 doi: 10.1016/j.jacl.2015.02.003

Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).

doi: 10.1136/bmj.39489.470347.AD

Powell, B. J. et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement. Sci. 10, 21 (2015).

pubmed: 25889199 pmcid: 4328074 doi: 10.1186/s13012-015-0209-1

Wilson, J. M. G. & Jungner, G. Principles and practice of screening for disease. WHO Chron. 22, 473 (1968).

Andermann, A., Blancquaert, I., Beauchamp, S. & Déry, V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ. 86, 317–319 (2008).

pubmed: 18438522 pmcid: 2647421 doi: 10.2471/BLT.07.050112

Falkner, B. & Gidding, S. Life-course implications of pediatric risk factors for cardiovascular disease. Can. J. Cardiol. 37, 766–775 (2021).

pubmed: 33581191 doi: 10.1016/j.cjca.2021.02.001

Luirink, I. et al. 20-Year follow-up of statins in children with familial hypercholesterolaemia. N. Engl. J. Med. 381, 1547–1556 (2019).

pubmed: 31618540 doi: 10.1056/NEJMoa1816454

Ibrahim, S., Reeskamp, L. F., Stroes, E. S. & Watts, G. F. Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. Curr. Opin. Lipidol. 31, 347–355 (2020).

pubmed: 33027222 doi: 10.1097/MOL.0000000000000714

Qureshi, N. et al. Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Cochrane Database Syst. Rev. 10, CD012985 (2021).

pubmed: 34617591

Jahn, B. et al. Familial hypercholesterolemia: a systematic review of modeling studies on screening interventions. Atherosclerosis 355, 15–29 (2022).

pubmed: 35870306 doi: 10.1016/j.atherosclerosis.2022.06.1011

Carvalho, C. et al. Application of a risk stratification tool for familial hypercholesterolaemia in primary care: an observational cross-sectional study in an unselected urban population. Heart 107, 1220–1225 (2021).

pubmed: 34016698 doi: 10.1136/heartjnl-2020-318714

Wald, D. S. et al. Child–parent familial hypercholesterolemia screening in primary care. N. Engl. J. Med. 375, 1628–1637 (2016).

pubmed: 27783906 doi: 10.1056/NEJMoa1602777

McKay, A. J. et al. Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost–utility analysis. Atherosclerosis 275, 434–443 (2018).

pubmed: 29937236 doi: 10.1016/j.atherosclerosis.2018.05.047

Klančar, G. et al. Universal screening for familial hypercholesterolemia in children. J. Am. Coll. Cardiol. 66, 1250–1257 (2015).

pubmed: 26361156 doi: 10.1016/j.jacc.2015.07.017

Matsunaga, K. et al. Universal screening for familial hypercholesterolemia in children in Kagawa, Japan. J. Atheroscler. Thromb. 29, 839–849 (2022).

pubmed: 34176852 doi: 10.5551/jat.62780

Morris, J. K., Wald, D. S. & Wald, N. J. The evaluation of cascade testing for familial hypercholesterolemia. Am. J. Med. Genet. A 158, 78–84 (2012).

doi: 10.1002/ajmg.a.34368

Wald, D. S. & Bestwick, J. P. Reaching detection targets in familial hypercholesterolaemia: comparison of identification strategies. Atherosclerosis 293, 57–61 (2020).

pubmed: 31837509 doi: 10.1016/j.atherosclerosis.2019.11.028

Murray, M. F. et al. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23, 989–995 (2021).

pubmed: 33727704 doi: 10.1038/s41436-020-01082-w

Grzymski, J. et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nat. Med. 26, 1235–1239 (2020).

pubmed: 32719484 doi: 10.1038/s41591-020-0982-5

Buchanan, A. H. et al. Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet. Med. 22, 1874–1882 (2020).

pubmed: 32601386 pmcid: 7605431 doi: 10.1038/s41436-020-0876-4

Khoury, M. J. & Dotson, W. D. From genes to public health: are we ready for DNA-based population screening? Genet. Med. 23, 996–998 (2021).

pubmed: 33790422 pmcid: 9215315 doi: 10.1038/s41436-021-01141-w

Held, P. K. et al. Analytical validation of familial hypercholesterolemia biomarkers in dried blood spots. Int. J. Neonatal Screen. 8, 14 (2022).

pubmed: 35225936 pmcid: 8883967 doi: 10.3390/ijns8010014

Downie, L., Halliday, J., Lewis, S. & Amor, D. J. Principles of genomic newborn screening programs: a systematic review. JAMA Netw. Open 4, e2114336 (2021).

pubmed: 34283230 pmcid: 8293022 doi: 10.1001/jamanetworkopen.2021.14336

Jones, L. K. et al. Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis. Implement. Sci. Commun. 2, 32 (2021).

pubmed: 33741054 pmcid: 7977494 doi: 10.1186/s43058-021-00135-8

Jones, L. K. et al. Barriers, facilitators, and solutions to familial hypercholesterolemia treatment. PLoS ONE 15, e0244193 (2020).

pubmed: 33362269 pmcid: 7757879 doi: 10.1371/journal.pone.0244193

Gidding, S. S. Familial hypercholesterolemia: the Atlantic Divide. J. Pediatr. https://doi.org/10.1016/j.jpeds.2022.09.021 (2022).

doi: 10.1016/j.jpeds.2022.09.021 pubmed: 36126732

Public Health England. Familial hypercholesterolaemia implementing a systems approach to detection and management. Public Health England https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/731873/familial_hypercholesterolaemia_implementation_guide.pdf (2018).

Peters, D. H., Tran, N. T. & Adam, T. Implementation research in health: a practical guide. WHO https://www.who.int/iris/bitstream/10665/91758/1/9789241506212_eng.pdf (2013).

Sturm, A. C. et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J. Am. Coll. Cardiol. 72, 662–680 (2018).

pubmed: 30071997 doi: 10.1016/j.jacc.2018.05.044

Ibrahim, S., Defesche, J. & Kastelein, J. J. P. Beyond the usual suspects: expanding on mutations and detection for familial hypercholesterolemia. Expert. Rev. Mol. Diagn. 21, 887–895 (2021).

pubmed: 34263698 doi: 10.1080/14737159.2021.1953985

Sniderman, A. D., Glavinovic, T. & Thanassoulis, G. Key questions about familial hypercholesterolemia: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 79, 1023–1031 (2022).

pubmed: 35272797 doi: 10.1016/j.jacc.2022.01.010

Sturm, A. C. et al. Limited-variant screening vs comprehensive genetic testing for familial hypercholesterolemia diagnosis. JAMA Cardiol. 6, 902–909 (2021).

pubmed: 34037665 pmcid: 8156154 doi: 10.1001/jamacardio.2021.1301

Gandhi, G. D. et al. Assessing the genetic burden of familial hypercholesterolemia in a large middle eastern biobank. J. Transl. Med. 20, 502 (2022).

pubmed: 36329474 pmcid: 9635206 doi: 10.1186/s12967-022-03697-w

Haralambos, K. et al. Clinical experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 240, 190–196 (2015).

pubmed: 25797312 doi: 10.1016/j.atherosclerosis.2015.03.003

Brunham, L. R. et al. Canadian cardiovascular society position statement on familial hypercholesterolemia: update 2018. Can. J. Cardiol. 34, 1553–1563 (2018).

pubmed: 30527143 doi: 10.1016/j.cjca.2018.09.005

Harada-Shiba, M. et al. Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022. J. Atheroscler. Thromb. https://doi.org/10.5551/jat.CR005 (2023).

doi: 10.5551/jat.CR005 pubmed: 37635059 pmcid: 10703578

Pina, A. et al. Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. Eur. J. Prev. Cardiol. 27, 1639–1646 (2020).

pubmed: 32019371 doi: 10.1177/2047487319898951

Correia, M., Kagenaar, E., van Schalkwijk, D. B., Bourbon, M. & Gama-Carvalho, M. Machine learning modelling of blood lipid biomarkers in familial hypercholesterolaemia versus polygenic/environmental dyslipidaemia. Sci. Rep. 11, 801 (2021).

doi: 10.1038/s41598-021-83392-w

Hesse, R., Raal, F. J., Endo, C., Blom, D. & George, J. A. Familial hypercholesterolemia identification by machine learning using lipid profile data performs as well as clinical diagnostic criteria. Circ. Genom. Precis. Med. 15, e003324 (2022).

pubmed: 36154661 doi: 10.1161/CIRCGEN.121.003324

Khoury, M. et al. The detection, evaluation, and management of dyslipidemia in children and adolescents: a Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update. Can. J. Cardiol. 38, 1168–1179 (2022).

pubmed: 35961755 doi: 10.1016/j.cjca.2022.05.002

Starr, B. et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 46, 791–803 (2008).

pubmed: 18601600 doi: 10.1515/CCLM.2008.135

Nohara, A. et al. Homozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 28, 665–678 (2021).

pubmed: 33867421 pmcid: 8265428 doi: 10.5551/jat.RV17050

France, M. et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis 255, 128–139 (2016).

pubmed: 27839699 doi: 10.1016/j.atherosclerosis.2016.10.017

Sjouke, B. et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome. Eur. Heart J. 36, 560–565 (2015).

pubmed: 24585268 doi: 10.1093/eurheartj/ehu058

Bertolini, S. et al. Homozygous familial hypercholesterolemia in Italy: clinical and molecular features. Atherosclerosis 312, 72–78 (2020).

pubmed: 32977124 doi: 10.1016/j.atherosclerosis.2020.08.027

Santos, R. D. et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 4, 850–861 (2016).

pubmed: 27246162 doi: 10.1016/S2213-8587(16)30041-9

Funabashi, S. et al. Substantially elevated atherosclerotic risks in Japanese severe familial hypercholesterolemia defined by the International Atherosclerosis Society. JACC Asia 1, 245–255 (2021).

pubmed: 36338164 pmcid: 9627852 doi: 10.1016/j.jacasi.2021.07.004

Langsted, A., Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A. & Nordestgaard, B. G. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 4, 577–587 (2016).

pubmed: 27185354 doi: 10.1016/S2213-8587(16)30042-0

Chan, D. C. et al. Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic? Clin. Chem. 65, 1258–1266 (2019).

pubmed: 31307996 doi: 10.1373/clinchem.2019.306738

Tromp, T. R. et al. Use of lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia. Atherosclerosis 365, 27–33 (2023).

pubmed: 36473758 doi: 10.1016/j.atherosclerosis.2022.11.020

Yeang, C., Witztum, J. L. & Tsimikas, S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J. Lipid Res. 62, 100053 (2021).

pubmed: 33636163 pmcid: 8042377 doi: 10.1016/j.jlr.2021.100053

Kronenberg, F. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 43, 3925–3946 (2022).

pubmed: 36036785 pmcid: 9639807 doi: 10.1093/eurheartj/ehac361

Yeang, C. et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 79, 1035–1046 (2022).

pubmed: 35300814 doi: 10.1016/j.jacc.2021.12.032

Brown, E. E. et al. Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association. J. Clin. Lipidol. 14, 398–413 (2020).

pubmed: 32507592 doi: 10.1016/j.jacl.2020.04.011

Khera, A. V. et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578–2589 (2016).

pubmed: 27050191 pmcid: 5405769 doi: 10.1016/j.jacc.2016.03.520

Paquette, M. et al. Effect of the LDL receptor mutation type on incident major adverse cardiovascular events in familial hypercholesterolaemia. Eur. J. Prev. Cardiol. 29, 2125–2131 (2022).

pubmed: 36047048 doi: 10.1093/eurjpc/zwac188

Landstrom, A. P. et al. Genetic testing for heritable cardiovascular diseases in pediatric patients: a scientific statement from the American Heart Association. Circ. Genom. Precis. Med. 14, e000086 (2021).

pubmed: 34412507 pmcid: 8546375 doi: 10.1161/HCG.0000000000000086

Musunuru, K. et al. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association. Circ. Genom. Precis. Med. 13, e000067 (2020).

pubmed: 32698598 doi: 10.1161/HCG.0000000000000067

Berberich, A. J. & Hegele, R. A. The advantages and pitfalls of genetic analysis in the diagnosis and management of lipid disorders. Best. Pract. Res. Clin. Endocrinol. Metab. 37, 101719 (2023).

pubmed: 36641373 doi: 10.1016/j.beem.2022.101719

Brown, E. E. The genetic counselor’s role in management of patients with dyslipidemia. Curr. Opin. Lipidol. 32, 83–88 (2021).

pubmed: 33492006 doi: 10.1097/MOL.0000000000000732

Marchand, M., Chen, V., Trinder, M., Cermakova, L. & Brunham, L. Patient perspectives regarding genetic testing for familial hypercholesterolemia. CJC Open 3, 557–564 (2020).

doi: 10.1016/j.cjco.2020.12.006

Berberich, A. J. & Hegele, R. A. The complex molecular genetics of familial hypercholesterolaemia. Nat. Rev. Cardiol. 16, 9–20 (2019).

pubmed: 29973710 doi: 10.1038/s41569-018-0052-6

Khera, A. V. & Hegele, R. A. What is familial hypercholesterolemia, and why does it matter? Circulation 141, 1760–1763 (2020).

pubmed: 32479201 pmcid: 7299543 doi: 10.1161/CIRCULATIONAHA.120.046961

Cao, Y.-X. et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia 1, 82–89 (2021).

pubmed: 36338372 pmcid: 9627923 doi: 10.1016/j.jacasi.2021.04.001

Leren, T. P. & Bogsrud, M. P. The importance of cascade genetic screening for diagnosing autosomal dominant hypercholesterolemia: results from twenty years of a national screening program in Norway. J. Clin. Lipidol. 15, 674–681 (2021).

pubmed: 34479846 doi: 10.1016/j.jacl.2021.08.007

Loh, W. J., Chan, D. C., Mata, P. & Watts, G. F. Familial hypercholesterolemia and elevated lipoprotein(a): cascade testing and other implications for contextual models of care. Front. Genet. 13, 905941 (2022).

pubmed: 35571022 pmcid: 9091303 doi: 10.3389/fgene.2022.905941

Jones, L. K. et al. Acceptability, appropriateness, and feasibility of automated screening approaches and family communication methods for identification of familial hypercholesterolemia: stakeholder engagement results from the IMPACT-FH study. J. Pers. Med. 11, 587 (2021).

pubmed: 34205662 pmcid: 8234213 doi: 10.3390/jpm11060587

Campbell-Salome, G. et al. Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. Transl. Behav. Med. 12, 800–809 (2022).

pubmed: 35429393 pmcid: 9291357 doi: 10.1093/tbm/ibac018

Leonardi-Bee, J. et al. Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis 338, 7–14 (2021).

pubmed: 34753031 doi: 10.1016/j.atherosclerosis.2021.09.014

Reijman, M. D., Kusters, D. M. & Wiegman, A. Advances in familial hypercholesterolaemia in children. Lancet Child. Adolesc. Health 5, 652–661 (2021).

pubmed: 34119028 doi: 10.1016/S2352-4642(21)00095-X

Pérez de Isla, L. et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry. Circulation 135, 2133–2144 (2017).

pubmed: 28275165 doi: 10.1161/CIRCULATIONAHA.116.024541

Bianconi, V., Banach, M. & Pirro, M. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc. Med. 31, 205–215 (2021).

pubmed: 32205033 doi: 10.1016/j.tcm.2020.03.004

Gallo, A., Mszar, R. & Miname, M. H. Updates on the use of subclinical atherosclerosis to predict risk of cardiovascular events in heterozygous familial hypercholesterolemia. Curr. Atheroscler. Rep. 24, 407–418 (2022).

pubmed: 35386094 doi: 10.1007/s11883-022-01017-7

Alonso, R. et al. Lipoprotein(a) levels in familial hypercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation. J. Am. Coll. Cardiol. 63, 1982–1989 (2014).

pubmed: 24632281 doi: 10.1016/j.jacc.2014.01.063

Ellis, K. L. et al. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J. Am. Coll. Cardiol. 73, 1029–1039 (2019).

pubmed: 30846097 doi: 10.1016/j.jacc.2018.12.037

Pérez de Isla, L. et al. A resilient type of familial hypercholesterolaemia: case–control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur. J. Prev. Cardiol. 29, 795–801 (2021).

doi: 10.1093/eurjpc/zwab185

Hedegaard, B. S. et al. Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 80, 1998–2010 (2022).

pubmed: 36396201 doi: 10.1016/j.jacc.2022.09.021

Nazli, S. A. et al. Familial hypercholesterolaemia and coronary risk factors among patients with angiogram-proven premature coronary artery disease in an Asian cohort. PLoS ONE 17, e0273896 (2022).

pubmed: 36054188 pmcid: 9439256 doi: 10.1371/journal.pone.0273896

Paquette, M. et al. Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 41, 2632–2640 (2021).

pubmed: 34433300 doi: 10.1161/ATVBAHA.121.316106

McKay, A. J., Gunn, L. H. & Ray, K. K. Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. Atherosclerosis 358, 68–74 (2022).

pubmed: 35953355 doi: 10.1016/j.atherosclerosis.2022.07.011

Agarwala, A. et al. Racial disparities in modifiable risk factors and statin usage in Black patients with familial hypercholesterolemia. J. Am. Heart Assoc. 10, e020890 (2021).

pubmed: 34431361 pmcid: 8649284 doi: 10.1161/JAHA.121.020890

Pérez de Isla, L. et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur. Heart J. 42, 2201–2211 (2021).

pubmed: 33437997 doi: 10.1093/eurheartj/ehaa1066

Funabashi, S. et al. Characterization of polyvascular disease in heterozygous familial hypercholesterolemia: its association with circulating lipoprotein(a) levels. J. Am. Heart Assoc. 11, e025232 (2022).

pubmed: 35929461 pmcid: 9496307 doi: 10.1161/JAHA.121.025232

Myers, K. D. et al. COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD. Am. J. Prev. Cardiol. 7, 100197 (2021).

pubmed: 34611637 pmcid: 8387291 doi: 10.1016/j.ajpc.2021.100197

Coutinho, E. R. et al. Familial hypercholesterolemia and cardiovascular disease in older individuals. Atherosclerosis 318, 32–37 (2021).

pubmed: 33450476 doi: 10.1016/j.atherosclerosis.2020.12.012

Iyen, B. et al. Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: a retrospective cohort study of the UK Simon Broome register linked to national hospital records. Atherosclerosis 315, 131–137 (2020).

pubmed: 33187671 pmcid: 7754706 doi: 10.1016/j.atherosclerosis.2020.10.895

Amrock, S. M. et al. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis 267, 19–26 (2017).

pubmed: 29080546 doi: 10.1016/j.atherosclerosis.2017.10.006

Zamora, A. et al. Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men. Sci. Rep. 13, 1492 (2023).

pubmed: 36707646 pmcid: 9883524 doi: 10.1038/s41598-023-27963-z

Klevmoen, M. et al. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis 335, 8–15 (2021).

pubmed: 34520888 doi: 10.1016/j.atherosclerosis.2021.09.003

Cho, L. et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 2602–2618 (2020).

pubmed: 32439010 pmcid: 8328156 doi: 10.1016/j.jacc.2020.03.060

Okoth, K. et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. Br. Med. J. 371, m3502 (2020).

doi: 10.1136/bmj.m3502

Bjelakovic, B. et al. Risk assessment and clinical management of children and adolescents with heterozygous familial hypercholesterolaemia. A position paper of the associations of preventive pediatrics of Serbia, mighty medic and international lipid expert panel. J. Clin. Med. 10, 4930 (2021).

pubmed: 34768450 pmcid: 8585021 doi: 10.3390/jcm10214930

Ramaswami, U. & Humphries, S. E. Management of familial hypercholesterolaemia in childhood. Curr. Opin. Pediatr. 32, 633–640 (2020).

pubmed: 32833799 doi: 10.1097/MOP.0000000000000943

Trinder, M. et al. Polygenic contribution to low-density lipoprotein cholesterol levels and cardiovascular risk in monogenic familial hypercholesterolemia. Circ. Genom. Precis. Med. 13, 515–523 (2020).

pubmed: 33079599 pmcid: 7889287 doi: 10.1161/CIRCGEN.120.002919

Fahed, A. C. et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat. Commun. 11, 3635 (2020).

pubmed: 32820175 pmcid: 7441381 doi: 10.1038/s41467-020-17374-3

Aragam, K. G. et al. Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease. J. Am. Coll. Cardiol. 75, 2769–2780 (2020).

pubmed: 32498804 pmcid: 7346975 doi: 10.1016/j.jacc.2020.04.027

Bolli, A., Di Domenico, P., Pastorino, R., Busby, G. B. & Bottà, G. Risk of coronary artery disease conferred by low-density lipoprotein cholesterol depends on polygenic background. Circulation 143, 1452–1454 (2021).

pubmed: 33677976 pmcid: 8021232 doi: 10.1161/CIRCULATIONAHA.120.051843

Christoffersen, M. & Tybjærg-Hansen, A. Polygenic risk scores: how much do they add? Curr. Opin. Lipidol. 32, 157–162 (2021).

pubmed: 33900274 doi: 10.1097/MOL.0000000000000759

Pérez de Isla, L. et al. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia. Arterioscler. Thromb. Vasc. Biol. 36, 2004–2010 (2016).

pubmed: 27444203 doi: 10.1161/ATVBAHA.116.307514

Kitahara, H. et al. Extent of lipid core plaque in patients with Achilles tendon xanthoma undergoing percutaneous coronary intervention for coronary artery disease. J. Cardiol. 79, 559–563 (2022).

pubmed: 34895790 doi: 10.1016/j.jjcc.2021.11.013

Mangili, L. C. et al. Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: a pilot study. Atherosclerosis 263, 393–397 (2017).

pubmed: 28499609 doi: 10.1016/j.atherosclerosis.2017.04.025

Tada, H. et al. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur. Heart J. 38, 1573–1579 (2017).

pubmed: 28159968 doi: 10.1093/eurheartj/ehx004

Michikura, M. et al. Association between Achilles tendon softness and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. J. Atheroscler. Thromb. 29, 1603–1612 (2022).

pubmed: 35013021 pmcid: 9623074 doi: 10.5551/jat.63151

Miname, M. H. et al. Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. Eur. Heart J. Cardiovasc. Imaging 21, 251–257 (2020).

pubmed: 31702778 doi: 10.1093/ehjci/jez280

Miname, M. H. et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. JACC Cardiovasc. Imaging 12, 1797–1804 (2019).

pubmed: 30448145 doi: 10.1016/j.jcmg.2018.09.019

Gallo, A. et al. The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia. JACC Cardiovasc. Imaging 14, 2414–2424 (2021).

pubmed: 34274263 doi: 10.1016/j.jcmg.2021.06.011

Miname, M. H. et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 213, 486–491 (2010).

pubmed: 20980000 doi: 10.1016/j.atherosclerosis.2010.10.001

Pérez de Isla, L. et al. Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study. J. Clin. Lipidol. 12, 948–957 (2018).

pubmed: 29753733 doi: 10.1016/j.jacl.2018.04.003

Pérez de Isla, L. et al. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: a computed tomographic angiography study. Atherosclerosis 317, 52–58 (2021).

pubmed: 33261814 doi: 10.1016/j.atherosclerosis.2020.11.012

Fuchs, A. et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort: a prospective observational cohort study. Ann. Intern. Med. 176, 433–442 (2023).

pubmed: 36972540 doi: 10.7326/M22-3027

Javaid, A. et al. Distribution of coronary artery calcium by age, sex, and race among patients 30–45 years old. J. Am. Coll. Cardiol. 79, 1873–1886 (2022).

pubmed: 35550683 pmcid: 9179003 doi: 10.1016/j.jacc.2022.02.051

Kusters, D. M., Wiegman, A., Kastelein, J. J. & Hutten, B. A. Carotid intima–media thickness in children with familial hypercholesterolemia. Circ. Res. 114, 307–310 (2014).

pubmed: 24192652 doi: 10.1161/CIRCRESAHA.114.301430

Stefanutti, C. et al. Toward an international consensus — integrating lipoprotein apheresis and new lipid-lowering drugs. J. Clin. Lipidol. 11, 858–871.e3 (2017).

pubmed: 28572002 doi: 10.1016/j.jacl.2017.04.114

Bélanger, A. M., Akioyamen, L. E., Ruel, I., Hales, L. & Genest, J. Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century. Eur. Heart J. 43, 3227–3239 (2022).

pubmed: 35776569 doi: 10.1093/eurheartj/ehac339

Zhang, R. et al. Supravalvular aortic stenosis and the risk of premature death among patients with homozygous familial hypercholesterolemia. Am. J. Cardiol. 145, 58–63 (2021).

pubmed: 33454344 doi: 10.1016/j.amjcard.2020.12.080

Zhang, Y. et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 6, 1406–1413 (2021).

pubmed: 34550307 pmcid: 8459309 doi: 10.1001/jamacardio.2021.3508

Masson, W. et al. Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: a systematic review. J. Clin. Lipidol. 16, 562–573 (2022).

pubmed: 35918256 doi: 10.1016/j.jacl.2022.07.004

Iyen, B., Akyea, R. K., Weng, S., Kai, J. & Qureshi, N. Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. Open Heart 8, e001817 (2021).

pubmed: 34702779 pmcid: 8549660 doi: 10.1136/openhrt-2021-001817

Perez de Isla, L. et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-Year SAFEHEART registry follow-up. J. Am. Coll. Cardiol. 67, 1278–1285 (2016).

pubmed: 26988947 doi: 10.1016/j.jacc.2016.01.008

Schwarz, A. et al. Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a). Lipids Health Dis. 21, 114 (2022).

pubmed: 36324160 pmcid: 9628073 doi: 10.1186/s12944-022-01708-9

Chua, Y.-A. et al. Attainment of low-density lipoprotein cholesterol targets and prescribing pattern of lipid-lowering medications among patients with familial hypercholesterolemia attending specialist clinics. J. Atheroscler. Thromb. https://doi.org/10.5551/jat.63389 (2022).

doi: 10.5551/jat.63389 pubmed: 36567112 pmcid: 10564645

Raal, F. J., Hovingh, G. K. & Catapano, A. L. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis 277, 483–492 (2018).

pubmed: 30270089 doi: 10.1016/j.atherosclerosis.2018.06.859

Brandts, J. & Ray, K. K. Familial hypercholesterolemia. J. Am. Coll. Cardiol. 78, 1831–1843 (2021).

pubmed: 34711342 doi: 10.1016/j.jacc.2021.09.004

Rosenson, R. S. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J. Lipid Res. 62, 100060 (2021).

pubmed: 33716107 pmcid: 8065289 doi: 10.1016/j.jlr.2021.100060

Ray, K. K. et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur. Heart J. 44, 129–138 (2022).

pmcid: 9825807 doi: 10.1093/eurheartj/ehac594

Lloyd-Jones, D. M. et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 80, 1366–1418 (2022).

pubmed: 36031461 doi: 10.1016/j.jacc.2022.07.006

Wong, N. D., Bang, M., Block, R. C., Peterson, A. L. & Karalis, D. G. Perceptions and barriers on the use of proprotein subtilisin/kexin type 9 inhibitors in heterozygous familial hypercholesterolemia (from a Survey of Primary Care Physicians and Cardiologists). Am. J. Cardiol. 152, 57–62 (2021).

pubmed: 34147211 doi: 10.1016/j.amjcard.2021.04.034

Langer, A. et al. Treatment inertia in patients with familial hypercholesterolemia. J. Am. Heart Assoc. 10, e020126 (2021).

pubmed: 34238023 pmcid: 8483494 doi: 10.1161/JAHA.120.020126

Ballantyne, C. M. et al. Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-label Extension Study). Am. J. Cardiol. 41, 1–11 (2022).

doi: 10.1016/j.amjcard.2022.03.020

Newman, C. B. Safety of statins and nonstatins for treatment of dyslipidemia. Endocrinol. Metab. Clin. North Am. 51, 655–679 (2022).

pubmed: 35963634 doi: 10.1016/j.ecl.2022.01.004

Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–1022 (2015).

pubmed: 25694464 pmcid: 4416140 doi: 10.1093/eurheartj/ehv043

Rosenson, R. S. et al. Optimizing cholesterol treatment in patients with muscle complaints. J. Am. Coll. Cardiol. 70, 1290–1301 (2017).

pubmed: 28859793 doi: 10.1016/j.jacc.2017.07.752

Mach, F. et al. Adverse effects of statin therapy: perception vs. the evidence — focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur. Heart J. 39, 2526–2539 (2018).

pubmed: 29718253 pmcid: 6047411 doi: 10.1093/eurheartj/ehy182

Newman, C. B. et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 39, e38–e81 (2019).

pubmed: 30580575 doi: 10.1161/ATV.0000000000000073

Nissen, S. E. et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N. Engl. J. Med. 388, 1353–1364 (2023).

pubmed: 36876740 doi: 10.1056/NEJMoa2215024

Fahed, A. C. et al. Association of the interaction between familial hypercholesterolemia variants and adherence to a healthy lifestyle with risk of coronary artery disease. JAMA Netw. Open 5, e222687 (2022).

pubmed: 35294538 pmcid: 8928007 doi: 10.1001/jamanetworkopen.2022.2687

Stone, N. J. et al. Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 819–836 (2022).

pubmed: 35210038 doi: 10.1016/j.jacc.2021.12.016

Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2019).

pubmed: 30415628 doi: 10.1056/NEJMoa1812792

Orringer, C. E., Jacobson, T. A. & Maki, K. C. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J. Clin. Lipidol. 13, 860–872 (2019).

pubmed: 31787586 doi: 10.1016/j.jacl.2019.10.014

Budoff, M. J. et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur. Heart J. 41, 3925–3932 (2020).

pubmed: 32860032 pmcid: 7654934 doi: 10.1093/eurheartj/ehaa652

Skulas-Ray, A. C. et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 140, e673–e691 (2019).

pubmed: 31422671 doi: 10.1161/CIR.0000000000000709

Visseren, F. L. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur. Heart J. 42, 3227–3337 (2021).

pubmed: 34458905 doi: 10.1093/eurheartj/ehab484

Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020).

pubmed: 32865380 doi: 10.1056/NEJMoa2021372

Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).

pubmed: 31733140 doi: 10.1056/NEJMoa1912388

Vuorio, A. et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst. Rev. 11, CD006401 (2019).

Anagnostis, P. et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine 69, 249–261 (2020).

pubmed: 32333266 doi: 10.1007/s12020-020-02302-8

Mamann, N. et al. Intermediate-term efficacy and tolerance of statins in children. J. Pediatr. 210, 161–165 (2019).

pubmed: 31053349 doi: 10.1016/j.jpeds.2019.03.032

Benekos, T., Kosmeri, C., Vlahos, A. & Milionis, H. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece. J. Pediatr. Endocrinol. Metab. 33, 533–538 (2020).

pubmed: 32084003 doi: 10.1515/jpem-2019-0250

Desai, N. K. et al. Hepatotoxicity of statins as determined by serum alanine aminotransferase in a pediatric cohort with dyslipidemia. J. Pediatr. Gastroenterol. Nutr. 68, 175 (2019).

pubmed: 30334928 pmcid: 6344263 doi: 10.1097/MPG.0000000000002174

Johnson, P. K. et al. Statin-associated myopathy in a pediatric preventive cardiology practice. J. Pediatr. 185, 94–98.e1 (2017).

pubmed: 28365026 pmcid: 6618290 doi: 10.1016/j.jpeds.2017.02.047

Joyce, N. R., Zachariah, J. P., Eaton, C. B., Trivedi, A. N. & Wellenius, G. A. Statin use and the risk of type 2 diabetes mellitus in children and adolescents. Acad. Pediatr. 17, 515–522 (2017).

pubmed: 28232259 pmcid: 5499509 doi: 10.1016/j.acap.2017.02.006

Kavey, R.-E. W. et al. Effectiveness and safety of statin therapy in children: a real-world clinical practice experience. CJC Open 2, 473–482 (2020).

pubmed: 33305206 pmcid: 7710927 doi: 10.1016/j.cjco.2020.06.002

Stein, E. A. et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr. 156, 231–236.e1–3 (2010).

pubmed: 19879596 doi: 10.1016/j.jpeds.2009.08.037

Kusters, D. M. et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J. Pediatr. 166, 1377–1384.e1–3 (2015).

pubmed: 25841542 doi: 10.1016/j.jpeds.2015.02.043

Santos, R. D. et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 1317–1327 (2020).

pubmed: 32865373 doi: 10.1056/NEJMoa2019910

Daniels, S. et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. J. Clin. Lipidol. 14, 322–330.e5 (2020).

pubmed: 32331936 doi: 10.1016/j.jacl.2020.03.001

Santos, R. D. et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 10, 732–740 (2022).

pubmed: 36075246 doi: 10.1016/S2213-8587(22)00221-2

Roy, G., Boucher, A., Couture, P. & Drouin-Chartier, J.-P. Impact of diet on plasma lipids in individuals with heterozygous familial hypercholesterolemia: a systematic review of randomized controlled nutritional studies. Nutrients 13, 235 (2021).

pubmed: 33561083 pmcid: 7829745 doi: 10.3390/nu13010235

Kris-Etherton, P. M. et al. Strategies for promotion of a healthy lifestyle in clinical settings: pillars of ideal cardiovascular health: a science advisory from the American Heart Association. Circulation 144, e495–e514 (2021).

pubmed: 34689589

Langslet, G. et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am. J. Prev. Cardiol. 6, 100180 (2021).

pubmed: 34327501 pmcid: 8315460 doi: 10.1016/j.ajpc.2021.100180

Hokanson, J. S. et al. Preventive medicine in pediatric cardiology practice. J. Pediatr. 253, 14–17.e3 (2022).

pubmed: 36027977 doi: 10.1016/j.jpeds.2022.08.034

Kinnear, F. J. et al. Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis. BMJ Open 9, e030290 (2019).

pubmed: 31371299 pmcid: 6677970 doi: 10.1136/bmjopen-2019-030290

Svendsen, K. et al. Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: examples from Scandinavia. Atherosclerosis 316, 48–52 (2021).

pubmed: 33302044 doi: 10.1016/j.atherosclerosis.2020.11.027

Mackie, T. I., Tse, L. L., de Ferranti, S. D., Ryan, H. R. & Leslie, L. K. Treatment decision making for adolescents with familial hypercholesterolemia: role of family history and past experiences. J. Clin. Lipidol. 9, 583–593.e1–3 (2015).

pubmed: 26228677 pmcid: 6594829 doi: 10.1016/j.jacl.2015.04.008

Alothman, L. et al. Health-related quality of life in homozygous familial hypercholesterolemia: a systematic review and meta-analysis. J. Clin. Lipidol. 16, 52–65 (2022).

pubmed: 35027327 doi: 10.1016/j.jacl.2021.11.014

Tunçel, Ö. K. et al. Mental status and physical activity in patients with homozygous familial hypercholesterolemia: a subgroup analysis of a nationwide survey (A-HIT1 registry). J. Clin. Lipidol. 14, 361–370. e2 (2020).

doi: 10.1016/j.jacl.2020.04.006

Nordestgaard, B. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (Consensus Statement of the European Atherosclerosis Society). Eur. Heart J. 34, 3478–3490 (2013).

pubmed: 23956253 pmcid: 3844152 doi: 10.1093/eurheartj/eht273

Cuchel, M. et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 35, 2146–2157 (2014).

pubmed: 25053660 pmcid: 4139706 doi: 10.1093/eurheartj/ehu274

Stefanutti, C. et al. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study. J. Clin. Lipidol. 13, 608–617 (2019).

pubmed: 31255589 doi: 10.1016/j.jacl.2019.05.002

Thompson, G. R. et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur. Heart J. 39, 1162–1168 (2018).

pubmed: 29106543 doi: 10.1093/eurheartj/ehx317

Kramer, A. I. et al. Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 29, 817–828 (2021).

doi: 10.1093/eurjpc/zwab224

Nurmohamed, N. S., Navar, A. M. & Kastelein, J. J. P. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B. J. Am. Coll. Cardiol. 77, 1564–1575 (2021).

pubmed: 33766264 doi: 10.1016/j.jacc.2020.11.079

Ray, K. K. et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur. Heart J. 43, 830–833 (2021).

doi: 10.1093/eurheartj/ehab718

Raal, F. J. et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385, 341–350 (2015).

pubmed: 25282520 doi: 10.1016/S0140-6736(14)61374-X

Bansal, S. et al. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J. Clin. Lipidol. 15, 814–821 (2021).

pubmed: 34750081 doi: 10.1016/j.jacl.2021.10.003

Santos, R. D. et al. Long-term evolocumab in patients with familial hypercholesterolemia. J. Am. Coll. Cardiol. 75, 565–574 (2020).

pubmed: 32057369 doi: 10.1016/j.jacc.2019.12.020

Bruckert, E. et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler. Thromb. Vasc. Biol. 42, 1447–1457 (2022).

pubmed: 36325897 pmcid: 9750107 doi: 10.1161/ATVBAHA.122.317793

Harada-Shiba, M. et al. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022. J. Atheroscler. Thromb. https://doi.org/10.5551/jat.CR006 (2023).

doi: 10.5551/jat.CR006 pubmed: 37635059 pmcid: 10703578

Sunil, B., Foster, C., Wilson, D. P. & Ashraf, A. P. Novel therapeutic targets and agents for pediatric dyslipidemia. Ther. Adv. Endocrinol. Metab. 12, 20420188211058323 (2021).

pubmed: 34868544 pmcid: 8637781 doi: 10.1177/20420188211058323

Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 711–720 (2020).

pubmed: 32813947 doi: 10.1056/NEJMoa2004215

Blom, D. J. et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation 136, 332–335 (2017).

pubmed: 28716835 doi: 10.1161/CIRCULATIONAHA.117.028208

Reeskamp, L. F. et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis 327, 13–17 (2021).

pubmed: 34004483 doi: 10.1016/j.atherosclerosis.2021.04.014

Stefanutti, C. & Thompson, G. R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr. Atheroscler. Rep. 17, 465 (2015).

pubmed: 25410046 doi: 10.1007/s11883-014-0465-6

Palcoux, J.-B. et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther. Apher. Dial. 12, 195–201 (2008).

pubmed: 18503695 doi: 10.1111/j.1744-9987.2008.00574.x

Hudgins, L. C., Kleinman, B., Scheuer, A., White, S. & Gordon, B. R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1199–1204 (2008).

pubmed: 18940291 doi: 10.1016/j.amjcard.2008.06.049

Græsdal, A. et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol. 6, 331–339 (2012).

pubmed: 22836070 doi: 10.1016/j.jacl.2012.03.004

Bajaj, A. & Cuchel, M. Advancements in the treatment of homozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 29, 1125–1135 (2022).

pubmed: 35466160 pmcid: 9371762 doi: 10.5551/jat.RV17065

Luirink, I. K. et al. Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: a systematic review. J. Clin. Lipidol. 13, 31–39 (2019).

pubmed: 30553758 doi: 10.1016/j.jacl.2018.10.011

Kawashiri, M.-a et al. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis 265, 225–230 (2017).

pubmed: 28926730 doi: 10.1016/j.atherosclerosis.2017.09.011

Chadwick, A. C., Evitt, N. H., Lv, W. & Musunuru, K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation 137, 975–977 (2018).

pubmed: 29483174 pmcid: 5830171 doi: 10.1161/CIRCULATIONAHA.117.031335

Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).

pubmed: 34012082 doi: 10.1038/s41586-021-03534-y

Al Dubayee, M., Kayikcioglu, M., van Lennep, J. R., Hergli, N. & Mata, P. Is liver transplant curative in homozygous familial hypercholesterolemia? A review of nine global cases. Adv. Ther. 39, 3042–3057 (2022).

pubmed: 35471728 pmcid: 9122866 doi: 10.1007/s12325-022-02131-3

Kazimi, M. et al. Concurrent living donor liver transplantation and off-pump coronary artery bypass in a five-year-old child with homozygous familial hypercholesterolemia: a case report. Transplant. Proc. https://doi.org/10.1016/j.transproceed.2023.02.024 (2023).

doi: 10.1016/j.transproceed.2023.02.024 pubmed: 36967336

El-Rassi, I., Chehab, G., Saliba, Z., Alawe, A. & Jebara, V. Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report and a review. J. Clin. Lipidol. 5, 329–332 (2011).

pubmed: 21784380 doi: 10.1016/j.jacl.2011.05.002

Ishigaki, Y. et al. Liver transplantation for homozygous familial hypercholesterolemia. J. Atheroscler. Thromb. 26, 121–127 (2019).

pubmed: 30555131 pmcid: 6365147 doi: 10.5551/jat.RV17029

Martinez, M. et al. Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia. Am. J. Cardiol. 118, 504–510 (2016).

pubmed: 27365335 doi: 10.1016/j.amjcard.2016.05.042

Cephus, C. E., Qureshi, A. M., Tejtel, S. K. S., Alam, M. & Moodie, D. S. Coronary artery disease in a child with homozygous familial hypercholesterolemia: regression after liver transplantation. J. Clin. Lipidol. 13, 880–886 (2019).

pubmed: 31704104 doi: 10.1016/j.jacl.2019.09.007

Mlinaric, M. et al. Case report: liver transplantation in homozygous familial hypercholesterolemia (HoFH) — long-term follow-up of a patient and literature review. Front. Pediatr. 8, 567895 (2020).

pubmed: 33163465 pmcid: 7581712 doi: 10.3389/fped.2020.567895

Ibrahim, M., El-Hamamsy, I., Barbir, M. & Yacoub, M. H. Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. J. Cardiovasc. Transl. Res. 5, 351–358 (2012).

pubmed: 21882079 doi: 10.1007/s12265-011-9311-1

Squires, J. E. et al. Factors associated with improved patient and graft survival beyond 1 year in pediatric liver transplantation. Liver Transpl. 28, 1899–1910 (2022).

pubmed: 35555876 doi: 10.1002/lt.26502

Cohen, H. & Stefanutti, C. Current approach to the diagnosis and treatment of heterozygote and homozygous FH children and adolescents. Curr. Atheroscler. Rep. 23, 30 (2021).

pubmed: 33963467 pmcid: 8105241 doi: 10.1007/s11883-021-00926-3

Perez de Isla, L. et al. Alicrocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolaemia: the ARCHITECT study. Circulation https://doi.org/10.1161/CIRCULATIONAHA.122.062557 (2023).

doi: 10.1161/CIRCULATIONAHA.122.062557 pubmed: 37747952 pmcid: 10158600

Sepucha, K. R. & Scholl, I. Measuring shared decision making: a review of constructs, measures, and opportunities for cardiovascular care. Circ. Cardiovasc. Qual. Outcomes 7, 620–626 (2014).

pubmed: 24867916 doi: 10.1161/CIRCOUTCOMES.113.000350

Barrett, B., Ricco, J., Wallace, M., Kiefer, D. & Rakel, D. Communicating statin evidence to support shared decision-making. BMC Fam. Pract. 17, 41 (2016).

pubmed: 27048421 pmcid: 4822230 doi: 10.1186/s12875-016-0436-9

Spatz, E. S. & Spertus, J. A. Shared decision making: a path toward improved patient-centered outcomes. Circ. Cardiovasc. Qual. Outcomes 5, e75–e77 (2012).

pubmed: 23170005 doi: 10.1161/CIRCOUTCOMES.112.969717

Birtcher, K. K. et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment: a framework for pragmatic, patient-centered care. J. Am. Coll. Cardiol. 81, 292–317 (2023).

pubmed: 36307329 doi: 10.1016/j.jacc.2022.08.754

Graham, D. F. & Raal, F. J. Management of familial hypercholesterolemia in pregnancy. Curr. Opin. Lipidol. 32, 370–377 (2021).

pubmed: 34619689 doi: 10.1097/MOL.0000000000000790

Amundsen, Å. L. et al. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 189, 451–457 (2006).

pubmed: 16466729 doi: 10.1016/j.atherosclerosis.2006.01.002

Nangrahary, M., Graham, D. F., Pang, J., Barnett, W. & Watts, G. F. Familial hypercholesterolaemia in pregnancy: Australian case series and review. Aust. N. Z. J. Obstet. Gynaecol. https://doi.org/10.1111/ajo.13657 (2023).

doi: 10.1111/ajo.13657 pubmed: 36883608

Johansen, A. K. et al. Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: novel data using repeated measurements during 12-years follow-up. Atheroscler 51, 28–34 (2023).

doi: 10.1016/j.athplu.2023.01.001

Cacciatore, F. et al. Maternal hypercholesterolaemia during pregnancy affects severity of myocardial infarction in young adults. Eur. J. Prev. Cardiol. 29, 758–765 (2022).

pubmed: 34662903 doi: 10.1093/eurjpc/zwab152

Balla, S., Ekpo, E. P., Wilemon, K. A., Knowles, J. W. & Rodriguez, F. Women living with familial hypercholesterolemia: challenges and considerations surrounding their care. Curr. Atheroscler. Rep. 22, 60 (2020).

pubmed: 32816232 pmcid: 7508565 doi: 10.1007/s11883-020-00881-5

Thorogood, M., Seed, M. & De Mott, K., Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. Br. J. Obstet. Gynaecol. 116, 478–479 (2009).

doi: 10.1111/j.1471-0528.2008.02084.x

Regitz-Zagrosek, V. et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur. Heart J. 39, 3165–3241 (2018).

pubmed: 30165544 doi: 10.1093/eurheartj/ehy340

Lawesson, S. S. et al. Association between history of adverse pregnancy outcomes and coronary artery disease assessed by coronary computed tomography angiography. J. Am. Med. Assoc. 329, 393–404 (2023).

doi: 10.1001/jama.2022.24093

Agarwala, A., Michos, E. D., Samad, Z., Ballantyne, C. M. & Virani, S. S. The use of sex-specific factors in the Assessment of Women’s Cardiovascular Risk. Circulation 141, 592–599 (2020).

pubmed: 32065772 pmcid: 7032610 doi: 10.1161/CIRCULATIONAHA.119.043429

Lewek, J. & Banach, M. Dyslipidemia management in pregnancy: why is it not covered in the guidelines? Curr. Atheroscler. Rep. 24, 547–556 (2022).

pubmed: 35499807 doi: 10.1007/s11883-022-01030-w

Pieper, P. G. Use of medication for cardiovascular disease during pregnancy. Nat. Rev. Cardiol. 12, 718 (2015).

pubmed: 26585398 doi: 10.1038/nrcardio.2015.172

Blaha, M., Lanska, M., Blaha, V., Boudys, L. & Zak, P. Pregnancy in homozygous familial hypercholesterolemia — importance of LDL-apheresis. Atheroscler. Suppl. 18, 134–139 (2015).

pubmed: 25936317 doi: 10.1016/j.atherosclerosissup.2015.02.024

Ogura, M. et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion. Atherosclerosis 254, 179–183 (2016).

pubmed: 27755983 doi: 10.1016/j.atherosclerosis.2016.10.018

Kusters, D. M. et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert. Rev. Cardiovasc. Ther. 10, 363–378 (2012).

pubmed: 22390808 doi: 10.1586/erc.11.196

Zarek, J., Delano, K. E., Nickel, C., Laskin, C. A. & Koren, G. Are statins teratogenic in humans? Addressing the safety of statins in light of potential benefits during pregnancy. Exp. Rev. Obstet. Gynecol. 8, 513–524 (2013).

doi: 10.1586/17474108.2013.842684

Winterfeld, U. et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. Br. J. Obstet. Gynaecol. 120, 463–471 (2013).

doi: 10.1111/1471-0528.12066

Karalis, D. G., Hill, A. N., Clifton, S. & Wild, R. A. The risks of statin use in pregnancy: a systematic review. J. Clin. Lipidol. 10, 1081–1090 (2016).

pubmed: 27678424 doi: 10.1016/j.jacl.2016.07.002

Vahedian-Azimi, A. et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 336, 1–11 (2021).

pubmed: 34601188 doi: 10.1016/j.atherosclerosis.2021.09.010

Botha, T. C., Pilcher, G. J., Wolmarans, K., Blom, D. J. & Raal, F. J. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies. Atherosclerosis 277, 502–507 (2018).

pubmed: 30270091 doi: 10.1016/j.atherosclerosis.2018.05.038

Thobani, A., Hassen, L., Mehta, L. S. & Agarwala, A. Management of hypercholesterolemia in pregnant women with atherosclerotic cardiovascular disease. Curr. Atheroscler. Rep. 23, 58 (2021).

pubmed: 34345940 doi: 10.1007/s11883-021-00957-w

Toleikyte, I., Retterstøl, K., Leren, T. P. & Iversen, P. O. Pregnancy outcomes in familial hypercholesterolemia — a registry-based study. Circulation 124, 1606–1614 (2011).

pubmed: 21911783 doi: 10.1161/CIRCULATIONAHA.110.990929

Chang, J.-C. et al. Perinatal outcomes after statin exposure during pregnancy. JAMA Netw. Open 4, e2141321 (2021).

pubmed: 34967881 pmcid: 8719244 doi: 10.1001/jamanetworkopen.2021.41321

Poornima, I. G., Pulipati, V. P., Brinton, E. A. & Wild, R. A. Update on statin use in pregnancy. Am. J. Med. 136, 12–14 (2022).

pubmed: 36150512 pmcid: 10575572 doi: 10.1016/j.amjmed.2022.08.029

Mauricio, R. & Khera, A. Statin use in pregnancy: is it time for a paradigm shift? Circulation 145, 496–498 (2022).

pubmed: 35157518 doi: 10.1161/CIRCULATIONAHA.121.058983

Lundberg, G. P. et al. Heart centers for women: historical perspective on formation and future strategies to reduce cardiovascular disease. Circulation 138, 1155–1165 (2018).

pubmed: 30354384 doi: 10.1161/CIRCULATIONAHA.118.035351

Geraghty, L. et al. Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors. Heart Lung Circ. 30, 9–17 (2021).

pubmed: 32843293 doi: 10.1016/j.hlc.2020.05.108

Baum, S. J. et al. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: results of the randomized, controlled, open-label DE LAVAL study. J. Clin. Lipidol. 13, 901–909 (2019).

pubmed: 31759938 doi: 10.1016/j.jacl.2019.10.003

Cuchel, M. et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381, 40–46 (2013).

pubmed: 23122768 doi: 10.1016/S0140-6736(12)61731-0

D’Erasmo, L. et al. Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. Eur. J. Prev. Cardiol. 29, 832–841 (2022).

pubmed: 34971394 doi: 10.1093/eurjpc/zwab229

Thompson, G. R. The scientific basis and future of lipoprotein apheresis. Ther. Apher. Dial. 26, 32–36 (2022).

pubmed: 34331508 doi: 10.1111/1744-9987.13716

Thompson, G. R. et al. Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. Atherosclerosis 243, 328–333 (2015).

pubmed: 26433113 doi: 10.1016/j.atherosclerosis.2015.09.029

Kayikcioglu, M. et al. Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of a nationwide survey (A-HIT1 registry). J. Clin. Lipidol. 13, 455–467 (2019).

pubmed: 30928440 doi: 10.1016/j.jacl.2019.02.001

Watts, G. F. et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler. Suppl. 12, 221–263 (2011).

pubmed: 21917530 doi: 10.1016/j.atherosclerosissup.2011.06.001

Padmanabhan, A. et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence‐based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J. Clin. Apher. 34, 171–354 (2019).

pubmed: 31180581 doi: 10.1002/jca.21705

McIntosh, S. et al. Patient voice and health education for familial hypercholesterolaemia. Health Educ. J. 8, 123–133 (2022).

doi: 10.1177/00178969211055976

Bulsara, C. et al. Awareness of familial hypercholesterolaemia in Australian primary care: a qualitative descriptive study. Aust. J. Gen. Pract. 50, 634–640 (2021).

pubmed: 34462767 doi: 10.31128/AJGP-04-21-5952

Bean, L. J. et al. DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23, 979–988 (2021).

pubmed: 33790423 doi: 10.1038/s41436-020-01083-9

Jones, L. K., Sturm, A. C. & Gionfriddo, M. R. Translating guidelines into practice via implementation science: an update in lipidology. Curr. Opin. Lipidol. 33, 336–341 (2022).

pubmed: 35779062 pmcid: 9640274 doi: 10.1097/MOL.0000000000000835

Bauer, M. S., Damschroder, L., Hagedorn, H., Smith, J. & Kilbourne, A. M. An introduction to implementation science for the non-specialist. BMC Psychol. 3, 32 (2015).

pubmed: 26376626 pmcid: 4573926 doi: 10.1186/s40359-015-0089-9

Sarkies, M. et al. Avoiding unnecessary hospitalisation for patients with chronic conditions: a systematic review of implementation determinants for hospital avoidance programmes. Implement. Sci. 15, 91 (2020).

pubmed: 33087147 pmcid: 7579904 doi: 10.1186/s13012-020-01049-0

Andermann, A., Blancquaert, I., Beauchamp, S. & Costea, I. Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Public Health Genom. 14, 9–16 (2011).

doi: 10.1159/000272898

Jones, L. K. et al. Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: a protocol. Res. Soc. Adm. Pharm. 16, 390–395 (2019).

doi: 10.1016/j.sapharm.2019.06.006

Bangash, H. et al. An implementation science framework to develop a clinical decision support tool for familial hypercholesterolemia. J. Pers. Med. 10, 67 (2020).

pubmed: 32717811 pmcid: 7565418 doi: 10.3390/jpm10030067

Lindell, O. P. et al. Clinical decision support for familial hypercholesterolemia (CDS-FH): rationale and design of a cluster randomized trial in primary care. Am. Heart J. 247, 132–148 (2022).

doi: 10.1016/j.ahj.2022.02.005

Jones, L. K. et al. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. Implement. Sci. 16, 40 (2021).

pubmed: 33849601 pmcid: 8045284 doi: 10.1186/s13012-021-01108-0

Proctor, E. K. et al. Implementation research in mental health services: an emerging science with conceptual, methodological, and training challenges. Adm. Policy Ment. Health 36, 24–34 (2009).

pubmed: 19104929 doi: 10.1007/s10488-008-0197-4

Michie, S., Van Stralen, M. M. & West, R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement. Sci. 6, 42 (2011).

pubmed: 21513547 pmcid: 3096582 doi: 10.1186/1748-5908-6-42

Martin, A. C., Gidding, S. S., Wiegman, A. & Watts, G. F. Known and unknowns in the care of paediatric familial hypercholesterolaemia. J. Lipid Res. 58, 1765–1776 (2017).

pubmed: 28701353 pmcid: 5580907 doi: 10.1194/jlr.S074039

National Audit Office. Introducing Integrated Care Systems: joining up local services to improve health outcomes. NAO https://www.nao.org.uk/reports/introducing-integrated-care-systems-joining-up-local-services-to-improve-health-outcomes (2022).

Desai, N. R., Farbaniec, M. & Karalis, D. G. Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin. Cardiol. 46, 13–21 (2022).

pubmed: 36267039 pmcid: 9849440 doi: 10.1002/clc.23935

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Articles similaires

Classifications MeSH